A turning point for clinical research in China?

The Lancet

Volumn 382, Issue 9895, 2013, Pages 835-836

  Wang, Chen ^a,b   Liu, Qian ^a  

^a BEIJING HOSPITAL   (China)

^b Pharmacopoeia Commission of the People's Republic of China   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE;

CARDIOVASCULAR DISEASE; CHINA; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; CLINICAL RESEARCH; DRUG EFFICACY; DRUG SAFETY; ENDOCRINE DISEASE; HEALTH CARE POLICY; HUMAN; LUNG EMBOLISM; NEUROLOGIC DISEASE; NOTE; ONCOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE;

EID: 84883550027     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)61804-8     Document Type: Note

References (5)

1. Yang G, Wang Y, Zeng Y.X., et al. Rapid health transition in China, 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet 2013; 381: 1987-2015.
2. Yuan HF, Xu WD, Hu HY Young Chinese doctors and the pressure of publication. Lancet 2013; 381: e4.
3. Ministry of Science and Technology of the People's Republic of China. The namelist of National Clinical Research Centres. http://www.most.gov.cn/tztg/ 201306/t20130608-106459.htm (accessed Aug 25, 2013).
4. Wang C, Zhai Z, Yang Y., et al. Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial. Chest 2010; 137: 254-62.
5. Clive K, Elie A, Anthony C., et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th edn: American College of Chest Physicians evidence-based clinical practice guidelines, Chest 2012; 141: e419S-94S.